CONTEXT: Second-generation antipsychotics (SGAs) are increasingly used in the treatment of many psychotic and nonpsychotic disorders. Unfortunately, SGAs are often associated with substantial weight gain, with no means to predict which patients are at greatest risk. OBJECTIVE: To identify single-nucleotide polymorphisms associated with antipsychotic drug–induced weight gain. DESIGN: Pharmacogenetic association study. SETTING: The discovery cohort was from a US general psychiatric hospital. Three additional cohorts were from psychiatric hospitals in the United States and Germany and from a European antipsychotic drug trial. PARTICIPANTS: The discovery cohort consisted of 139 pediatric patients undergoing first exposure to SGAs. The 3 additional cohorts consisted of 73, 40, and 92 subjects. INTERVENTION: Patients in the discovery cohort were treated with SGAs for 12 weeks. Additional cohorts were treated for 6 and 12 weeks. MAIN OUTCOME MEASURES: We conducted a genomewide association study assessing weight gain associated with 12 weeks of SGA treatment in patients undergoing first exposure to antipsychotic drugs. We next genotyped 3 independent cohorts of subjects assessed for antipsychotic drug-induced weight gain. RESULTS: Our genome-wide association study yielded 20 single-nucleotide polymorphisms at a single locus exceeding a statistical threshold of P<10(-5). This locus, near the melanocortin 4 receptor (MC4R) gene, overlaps a region previously identified by large-scale genome-wide association studies of obesity in the general population. Effects were recessive, with minor allele homozygotes gaining extreme amounts of weight during the 12-week trial. These results were replicated in 3 additional cohorts, with rs489693 demonstrating consistent recessive effects; meta-analysis revealed a genome-wide significant effect (P=5.59 X 10 (-12). Moreover, we observed consistent effects on related metabolic indices, including triglyceride, leptin, and insulin levels. CONCLUSIONS: These data implicate MC4R in extreme SGA-induced weight gain and related metabolic disturbances. A priori identification of high-risk subjects could lead to alternative treatment strategies in this population.
CONTEXT: Second-generation antipsychotics (SGAs) are increasingly used in the treatment of many psychotic and nonpsychotic disorders. Unfortunately, SGAs are often associated with substantial weight gain, with no means to predict which patients are at greatest risk. OBJECTIVE: To identify single-nucleotide polymorphisms associated with antipsychotic drug–induced weight gain. DESIGN: Pharmacogenetic association study. SETTING: The discovery cohort was from a US general psychiatric hospital. Three additional cohorts were from psychiatric hospitals in the United States and Germany and from a European antipsychotic drug trial. PARTICIPANTS: The discovery cohort consisted of 139 pediatric patients undergoing first exposure to SGAs. The 3 additional cohorts consisted of 73, 40, and 92 subjects. INTERVENTION: Patients in the discovery cohort were treated with SGAs for 12 weeks. Additional cohorts were treated for 6 and 12 weeks. MAIN OUTCOME MEASURES: We conducted a genomewide association study assessing weight gain associated with 12 weeks of SGA treatment in patients undergoing first exposure to antipsychotic drugs. We next genotyped 3 independent cohorts of subjects assessed for antipsychotic drug-induced weight gain. RESULTS: Our genome-wide association study yielded 20 single-nucleotide polymorphisms at a single locus exceeding a statistical threshold of P<10(-5). This locus, near the melanocortin 4 receptor (MC4R) gene, overlaps a region previously identified by large-scale genome-wide association studies of obesity in the general population. Effects were recessive, with minor allele homozygotes gaining extreme amounts of weight during the 12-week trial. These results were replicated in 3 additional cohorts, with rs489693 demonstrating consistent recessive effects; meta-analysis revealed a genome-wide significant effect (P=5.59 X 10 (-12). Moreover, we observed consistent effects on related metabolic indices, including triglyceride, leptin, and insulin levels. CONCLUSIONS: These data implicate MC4R in extreme SGA-induced weight gain and related metabolic disturbances. A priori identification of high-risk subjects could lead to alternative treatment strategies in this population.
Authors: Andrés Martin; Lawrence Scahill; George M Anderson; Michael Aman; L Eugene Arnold; James McCracken; Christopher J McDougle; Elaine Tierney; Shirley Chuang; Benedetto Vitiello Journal: Am J Psychiatry Date: 2004-06 Impact factor: 18.112
Authors: Alkes L Price; Nick J Patterson; Robert M Plenge; Michael E Weinblatt; Nancy A Shadick; David Reich Journal: Nat Genet Date: 2006-07-23 Impact factor: 38.330
Authors: Shaun Purcell; Benjamin Neale; Kathe Todd-Brown; Lori Thomas; Manuel A R Ferreira; David Bender; Julian Maller; Pamela Sklar; Paul I W de Bakker; Mark J Daly; Pak C Sham Journal: Am J Hum Genet Date: 2007-07-25 Impact factor: 11.025
Authors: John C Chambers; Paul Elliott; Delilah Zabaneh; Weihua Zhang; Yun Li; Philippe Froguel; David Balding; James Scott; Jaspal S Kooner Journal: Nat Genet Date: 2008-05-04 Impact factor: 38.330
Authors: Delbert G Robinson; Margaret G Woerner; Barbara Napolitano; Raman C Patel; Serge M Sevy; Handan Gunduz-Bruce; Jose M Soto-Perello; Alan Mendelowitz; Ali Khadivi; Rachel Miller; Joanne McCormack; Beth S Lorell; Martin L Lesser; Nina R Schooler; John M Kane Journal: Am J Psychiatry Date: 2006-12 Impact factor: 18.112
Authors: René S Kahn; W Wolfgang Fleischhacker; Han Boter; Michael Davidson; Yvonne Vergouwe; Ireneus P M Keet; Mihai D Gheorghe; Janusz K Rybakowski; Silvana Galderisi; Jan Libiger; Martina Hummer; Sonia Dollfus; Juan J López-Ibor; Luchezar G Hranov; Wolfgang Gaebel; Joseph Peuskens; Nils Lindefors; Anita Riecher-Rössler; Diederick E Grobbee Journal: Lancet Date: 2008-03-29 Impact factor: 79.321
Authors: E J Brandl; A K Tiwari; C C Zai; E L Nurmi; N I Chowdhury; T Arenovich; M Sanches; V F Goncalves; J J Shen; J A Lieberman; H Y Meltzer; J L Kennedy; D J Müller Journal: Pharmacogenomics J Date: 2015-09-01 Impact factor: 3.550
Authors: Harald Murck; Thomas Laughren; Femke Lamers; Rosalind Picard; Sebastian Walther; Donald Goff; Stephen Sainati Journal: Innov Clin Neurosci Date: 2015 Mar-Apr
Authors: Aaron Jenkins; José A Apud; Fengyu Zhang; Heather Decot; Daniel R Weinberger; Amanda J Law Journal: Neuropsychopharmacology Date: 2014-03-14 Impact factor: 7.853